Abstract Library

#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mansfield A

Authors: Mansfield A, Aggarwal R, Beltran H, Farago A, Hann C,

Keywords: Rovalpituzumab tesirine, DLL3, neuroendocrine tumors, antibody-drug conjugate,

#1498 Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-center, Open-label, Dose-escalation Study

Introduction: PAS, a next generation SSA, is investigated to determine the maximum tolerated dose (MTD) in pts with advanced NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Yao J, Chan J, Mita A, Kundu M, Valera S,

Keywords: Pasireotide, MTD,

#869 Phase 1 Expansion Study of an Oral TORC1/TORC2 Kinase Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Introduction: Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223 is an ATP-competitive inhibitor of the mTOR kinase, inhibiting both TORC1 and TORC2.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Meyer T, Mahipal A, Bendell J, Nemunaitis J, Mita M,

Keywords: TORC-1 CC-223,

#195 UMB-4 as New Monoclonal Somatostatin Receptor Antibody: Correlation of Immunostaining with Molecular Imaging using Somatostatin Receptor PET/CT

Introduction: Somatostatin receptors (SSTR) are known for an overexpression in neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Kaemmerer D, Peter L, Lupp A, Schulz S, Prasad V,

Keywords: clone UMB-4, molecular imaging, neuroendocrine tumor, somatostatin receptor, monoclonal antibodies,

#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies

Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Götze L

Authors: Kaemmerer D, Götze L, Amelie L, Schulz S, Sänger J,

Keywords: molecular imaging, somatostatin receptors SSTR, neuroendocrine tumor, monoclonal and polyclonal antibodies, UMB-1,